CommercialCoverageMedium impact
Bioimpedance Devices for Detection and Management of Breast Cancer Related Lymphedema 2.01.52
Excellus BlueCross BlueShield·Oncology, General Surgery, Plastic Surgery·Miscellaneous
Effective date
Jan 22, 2026
We identified it
Jun 20, 2026
Summary
Excellus BlueCross BlueShield has established new medical necessity criteria for bioimpedance spectroscopy (BIS) devices used to detect and manage breast cancer-related lymphedema, effective January 22, 2026. The policy covers BIS for diagnosis and surveillance of subclinical lymphedema in patients with specific breast cancer treatment histories, with detailed screening intervals ranging from every 3 months in years 1-3 to annually after year 6.
Action Required
Before January 22, 2026: Billing team must update prior authorization processes for bioimpedance spectroscopy claims to verify patients meet ALL required criteria: history of breast cancer treatment PLUS one of six specific conditions (axillary lymph node dissection, sentinel lymph node biopsy with >6 nodes removed, regional node irradiation, taxane-based chemotherapy, sentinel lymph node biopsy with BMI >30, or mastectomy with invasive breast cancer). Update encounter forms to document these specific requirements. Claims not meeting all criteria will be considered investigational and denied.